Products Affected - Description
Allopurinol injection, West-Ward (formerly Bedford product)
500 mg vial (NDC 55390-0106-01)
Reason for the Shortage
West-Ward Pharmaceuticals’ parent company, Hikma Pharmaceuticals, acquired several products from Bedford Laboratories in July 2014 including allopurinol injection. West-Ward is not actively marketing allopurinol injection at this time.
Aloprim injection, Mylan Institutional
500 mg vial (NDC 67457-0187-50)
Estimated Resupply Dates
Mylan Institutional has been supplying the market for several months.
December 2, 2014; September 3, 2014; June 2, 2014; March 4, 2014; December 16, 2013; October 21, 2013; September 18, 2013; July 18, 2013; June 12, 2013; May 3, 2013; March 5, 2013, University of Utah, Drug Information Service. Copyright 2014, Drug Information Service, University of Utah, Salt Lake City, UT.
This information is provided through the support of Vizient to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Vizient, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Vizient, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Vizient, ASHP nor University of Utah endorses or recommends the use of any drug.
« Back to Drug Shortage Product Bulletins